RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Single-Cell Sequencing Combined with RNA Sequencing Reveals the Role of Natural Killer Cells in Prognosis and Immunotherapy Response in Cervical Squamous Cell Carcinoma.
Single-Cell Sequencing Combined with RNA Sequencing Reveals the Role of Natural Killer Cells in Prognosis and Immunotherapy Response in Cervical Squamous Cell Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
宫颈鳞状细胞癌(CSCC)预后不佳,治疗面临重大挑战。自然杀伤(NK)细胞在抗肿瘤免疫中发挥关键作用,但NK细胞与CSCC异质性及预后的相关性尚未得到明确阐释。
本研究旨在明确高活性NK细胞相关基因对CSCC预后和免疫治疗的潜在价值。研究者分别从TCGA和EMBL-EBI数据库获取CSCC患者的转录组和单细胞测序数据。对单细胞数据进行质量控制、降维,并鉴定高活性NK细胞及其标志基因。随后应用加权基因共表达网络分析(WGCNA)筛选NK细胞相关基因。研究采用单因素Cox、LASSO Cox回归及多因素Cox回归分析构建预后风险模型,并通过免疫浸润评估、生存分析、基因集富集分析、肿瘤突变分析及药物敏感性预测验证模型的临床意义。研究鉴定出CSCC中的高活性NK细胞及相关基因,并建立基于高活性NK细胞相关基因的预后风险模型,获得六个关键预后基因(RIPOR2、PTGER4、BIN2、MARCHF2、SPATA13和KLRC2)。该模型在训练集和验证集中均表现出稳健的预测性能。低风险组患者的NK细胞、CD8+ T细胞和树突状细胞浸润水平较高,对免疫检查点抑制剂治疗也更敏感。
此外,药物敏感性分析发现了有前景的候选疗法。本研究整合单细胞与RNA测序,揭示CSCC中NK细胞的异质性;所构建的预后风险模型为CSCC患者提供了预后生物标志物和治疗靶点,并为免疫治疗研究提供理论基础。
Cervical squamous cell carcinoma (CSCC) has an unfavorable prognosis with major therapeutic challenges. Natural killer (NK) cells play a pivotal function in anti-tumor immunity.
However, the correlation between NK cells and heterogeneity and prognosis in CSCC lacks definitive understanding.
This study seeks to elucidate the potential value of high-activity NK cell-related genes in prognosis and immunotherapy for CSCC. Transcriptome and single-cell sequencing data of people with CSCC were obtained from TCGA and EMBL-EBI databases, respectively. Single-cell data underwent quality control, dimensionality reduction, and identification of high-activity NK cells and their marker genes. After WGCNA application to screen NK-related genes. a prognostic risk model was constructed employing univariate Cox, LASSO Cox regression, and multivariate Cox regression analyses.
The clinical implication of the model was validated through immune infiltration assessment, survival, gene set enrichment, tumor mutation analyses, and drug sensitivity prediction. High-activity NK cells and associated genes in CSCC were identified. A risk prognostic model based on high-activity NK-related genes was developed, yielding six key prognostic genes (RIPOR2, PTGER4, BIN2, MARCHF2, SPATA13, KLRC2).
The model demonstrated robust predictive performance in training and validation sets. Patients in the low-risk group exhibited higher infiltration levels of NK, CD8+ T, and dendritic cells, along with increased sensitivity to immune checkpoint inhibitor therapy.
Additionally, drug sensitivity analysis identified promising therapeutic candidates.
This study, integrating single-cell and RNA sequencing, revealed the heterogeneity of NK cells in CSCC. The risk prognostic model provided prognostic biomarkers and therapeutic targets for CSCC patients, offering a theoretical foundation for immunotherapy research.
MEMBER ACCOUNT
登录成功会直接打开下一页。